重症喘息 – Medxy AI

2026 Global Initiative for Asthma (GINA) Strategy Report: Executive Summary and Key Changes

By MedXY 10/15/2026

A concise, practice-focused summary of the 2026 GINA Strategy Report, highlighting new recommendations on inhaled corticosteroid–formoterol (AIR) strategies, severe asthma biologic guidance, and acute care updates.

Allergy & Immunology news Respiratory

Trajectory of Exacerbations in Biologic-Eligible Severe Asthma: Insights from UK Nationwide Data

By MedXY 10/11/2026

A large UK study reveals that over two-thirds of biologic-eligible severe asthma patients improve without biologic therapy, identifying distinct exacerbation trajectories linked to blood eosinophil levels and disease phenotype.

Clinical Updates news Respiratory

Biologic Outcomes in Severe Asthma by Smoking Status: Insights from the SHARP European Registry

By MedXY 09/26/2026

SHARP registry data reveal that biologic therapies improve clinical outcomes equally in severe asthma patients irrespective of smoking status, challenging prevailing prescribing hesitancy and advocating inclusive treatment approaches.

Clinical Updates news Respiratory

Early Biologic Initiation in Severe Asthma: Enhancing Remission and Clinical Outcomes from Global Real-World Cohorts

By MedXY 09/16/2026

Earlier initiation of biologic therapies in severe asthma improves clinical remission rates, reduces exacerbations, preserves lung function, and decreases corticosteroid dependence, supporting a shift from reserving to preserving treatment paradigms.